Skip to content


The incidence of Ductal Carcinoma In Situ (‘DCIS’ or Stage 0 disease) increased five-fold from the 1970s to the 2000s (5.8 to 32.5 per 100,000 women), primarily due to increased use of breast screening. Around 25% of breast cancers diagnosed in the United States are DCIS, adding up to more than 55,000 women every year[1].

Current treatment often includes external beam radiotherapy (SBRT), either delivered intra-operatively or after surgery, with post-operative radiotherapy the preferred option for the majority of patients with early-stage breast cancer[2].

YntraDose can be directly implanted into the tumour bed following tissue-conserving lumpectomy during the course of the operation. This confers several advantages over external radiotherapy, including reduced patient visits, improved patient compliance, no capital equipment and operational and resource efficiency savings for healthcare providers.

Ongoing evaluation of the safety profile of YntraDose in 13 patients have shown YntraDose to be safe and well tolerated. Preliminary effectiveness and safety data will be analysed by a Data Monitoring Committee in due course.